Stockreport

Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight [Yahoo! Finance]

Immunovant, Inc.  (IMVT) 
PDF IMVT-1402 (Immunovant/Roivant Sciences), Descartes-08 (Cartesian Therapeutics), Remibrutinib (Novartis), FABHALTA (Iptacopan) (Novartis), Gefurulimab (Alexion AstraZenec [Read more]